Author

Qingcai Meng

National Institutes of HealthORCID 0000-0001-5906-8366Unclaimed ORCID profile · follow to get notified of new preprints

Additional preprints under this name without ORCID

Qingcai Meng1 paper · National Institutes of Diabetes and Digestive and Kidney Diseases, National Institutes of Health;

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

Aaliyah BattleiD· 1 shared Arnold BolomskyiD· 1 shared Björn HäupliD· 1 shared Callie K. VanWinkleiD· 1 shared Elizabeth HilliD· 1 shared Jagan R. MuppidiiD· 1 shared James D. PhelaniD· 1 shared Lin ZhangiD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Aaliyah BattleORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Phosphorylation Protects Oncogenic RAS from LZTR1-Mediated Degradation

Lin Zhang, Arnold Bolomsky, Omar S. Al‐Odat, Callie K. VanWinkle, Aaliyah Battle, Papiya Chakraborty, Ronald J. Holewinski, Þorkell Andrésson, Björn Häupl, Thomas Oellerich, Elizabeth Hill, Mehmet Hakan Kocoglu, Qingcai Meng, James D. Phelan, Jagan R. Muppidi, Ryan M. Young

This study identifies phosphorylation as a mechanism protecting oncogenic RAS from LZTR1-mediated degradation, with implications for targeting RAS stability in hematologic cancers.

Blood Cancer Discovery · Aug 31, 2026Peer-reviewedCancer Biology